0Y5E Stock Overview Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Perrigo Company plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Perrigo Historical stock prices Current Share Price US$26.30 52 Week High US$34.24 52 Week Low US$20.00 Beta 0.52 1 Month Change -2.20% 3 Month Change -5.33% 1 Year Change -15.49% 3 Year Change -33.49% 5 Year Change -49.70% Change since IPO -71.38%
Recent News & Updates
Independent Director recently sold US$497k worth of stock Dec 11
Upcoming dividend of US$0.28 per share Nov 25
Third quarter dividend of US$0.28 announced Nov 11
Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023) Nov 07
Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024 Nov 07
Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024 Nov 02 See more updates
Independent Director recently sold US$497k worth of stock Dec 11
Upcoming dividend of US$0.28 per share Nov 25
Third quarter dividend of US$0.28 announced Nov 11
Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023) Nov 07
Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024 Nov 07
Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024 Nov 02
Perrigo Company plc to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary Sep 04
Upcoming dividend of US$0.28 per share Aug 26
Advisor recently sold US$969k worth of stock Aug 23
Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer Aug 19
Second quarter dividend of US$0.28 announced Aug 11
Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023) Aug 03 Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024
Perrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024 Jul 20
Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc. Jul 11
Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024 Jun 13
Perrigo Company plc Announces Executive Changes May 30
Upcoming dividend of US$0.28 per share May 24 Perrigo Company plc Reaffirms Earnings Guidance for 2024
New major risk - Financial position May 08
First quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023) May 08
Fourth quarter dividend of US$0.28 announced May 06
Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024 May 01
Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million. Apr 26
Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024 Apr 24
Perrigo Company plc, Annual General Meeting, May 02, 2024 Mar 23
Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors Mar 09
Fourth quarter dividend increased to US$0.28 Mar 04
Perrigo Company plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 Mar 01 Perrigo Company plc Reports Earnings Guidance for the Fiscal Year 2024
Full year 2023 earnings released: US$0.033 loss per share (vs US$0.97 loss in FY 2022) Feb 29
Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024 Feb 27
Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024 Feb 14
Upcoming dividend of US$0.27 per share at 3.6% yield Nov 23 Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023 Nov 08
Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Perrigo Company plc Announces Executive Changes Sep 12
Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023 Aug 10
Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive Jul 14 Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive Officer Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge
Perrigo Company plc Announces FDA Approval of Opill®? for Over-The-Counter Use May 11 Perrigo Company plc Reaffirms Sales Guidance for the Fiscal Year 2023
Perrigo Announces Quarterly Dividend, Payable on June 20, 2023 May 05
Perrigo Company plc to Report Q4, 2022 Results on Feb 27, 2023 Feb 15
Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of Directors Feb 10
Perrigo Company plc Provides Earnings Guidance for the Fiscal Year 2022 Nov 09
Perrigo Company plc Announces Quarterly Dividend, Payable on December 20, 2022 Nov 04
Perrigo Company plc (NYSE:PRGO) acquired Good Start Packaging, Inc. from Nestle Canada Inc. Nov 03
Perrigo Company plc to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Perrigo Company plc Announces Litigation Update Aug 18
Perrigo Company Revised Earnings Guidance for the Full Year of 2022 Aug 10
Perrigo Company plc Declares Quarterly Dividend, Payable on September 20, 2022 Aug 03
Perrigo Company plc to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Perrigo Company plc Appoints Albert A. Manzone to Serve as A Member of the Board of Directors and Member of the Talent & Compensation Committee, to Be Effective July 30, 2022 Jul 15
Perrigo Company plc Promotes Alison Ives to Executive Vice President and Chief Scientific Officer Jun 03
Perrigo Company plc Announces U.S. FDA Approval for Omeprazole Magnesium Delayed-Release Mini Capsules May 27
Perrigo Company plc Announces Retirement of Todd Kingma as Executive Vice President, General Counsel, and Corporate Secretary, Effective August 31, 2022 May 13 Perrigo Company plc Raises Earnings Guidance for the Fiscal Year 2022
Perrigo Company plc Declares Quarterly Dividend, Payable on June 21, 2022 May 06
Perrigo Company plc Provides Earnings Guidance for the Year 2022 Mar 03
Perrigo Company plc Announces Quarterly Dividend, Payable on March 17, 2022 Feb 17
Perrigo Company plc to Report Q4, 2021 Results on Mar 01, 2022 Feb 16
Perrigo Company plc(TASE:PRGO) dropped from TA-35 Index Feb 09
Perrigo Announces Voluntary Delisting from the Tel Aviv Stock Exchange Nov 24
Third quarter 2021 earnings released: US$0.40 loss per share (vs US$1.13 loss in 3Q 2020) Nov 11
Perrigo Company plc (NYSE:PRGO) signed a binding offer to acquire HRA Pharma, SA from funds affiliated with Astorg Partners and Goldman Sachs Asset Management, L.P. for transaction value of €1.8 billion. Sep 10
Upcoming dividend of US$0.24 per share Aug 26
Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.44 profit in 2Q 2020) Aug 12
Upcoming dividend of US$0.24 per share May 27
First quarter 2021 earnings released: EPS US$0.021 (vs US$0.78 in 1Q 2020) May 12
Perrigo Company plc Reaffirms Outlook for the Fiscal Year 2021 May 12
Key Executive recently sold US$110k worth of stock Mar 14
Altaris Capital Partners, LLC reached a definitive agreement to acquire Generic Rx Pharmaceuticals business of Perrigo Company plc (NYSE:PRGO) for approximately $1.6 billion. Mar 03
Revenue misses expectations Mar 02
Full year 2020 earnings released: US$1.20 loss per share (vs US$1.07 profit in FY 2019) Mar 02
Probi and Perrigo Sign Extensive Pan-European Agreement for Launch of Probiotic Concepts Feb 18
Perrigo Company plc to Report Q4, 2020 Results on Mar 01, 2021 Feb 17
Perrigo and Michigan State University Announce Partnership to Advance Consumer Self-Care Innovation Jan 12
Perrigo Company plc Appoints D Orlando D. Ashford to Serve as Member of Board of Directors Dec 17 Shareholder Returns 0Y5E GB Pharmaceuticals GB Market 7D -4.0% -0.9% -1.4% 1Y -15.5% -0.6% 4.6%
See full shareholder returns
Return vs Market: 0Y5E underperformed the UK Market which returned 4.6% over the past year.
Price Volatility Is 0Y5E's price volatile compared to industry and market? 0Y5E volatility 0Y5E Average Weekly Movement 4.3% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.3% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0Y5E has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0Y5E's weekly volatility (4%) has been stable over the past year.
About the Company Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Show more Perrigo Company plc Fundamentals Summary How do Perrigo's earnings and revenue compare to its market cap? 0Y5E fundamental statistics Market cap US$3.60b Earnings (TTM ) -US$146.90m Revenue (TTM ) US$4.39b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0Y5E income statement (TTM ) Revenue US$4.39b Cost of Revenue US$2.81b Gross Profit US$1.58b Other Expenses US$1.73b Earnings -US$146.90m
Last Reported Earnings
Sep 28, 2024
Earnings per share (EPS) -1.08 Gross Margin 36.07% Net Profit Margin -3.34% Debt/Equity Ratio 104.8%
How did 0Y5E perform over the long term?
See historical performance and comparison Dividends
4.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 21:08 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/28 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Perrigo Company plc is covered by 38 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Ishan Majumdar Baptista Research Douglas Tsao Barclays
Show 35 more analysts 